Cancer therapeutics-related cardiac dysfunction(CTRCD)is receiving more attention.Risk factors assessment before cancer therapy,cardiac function monitoring during and after cancer therapy,and early detection and treatment of myocardial injury are key to preventing clinical heart failure.The incidence and severity of cardiotoxicity can be reduced by measures such as reducing drug dose,adjusting administration route,and using low toxic drugs.Cardioprotective agents including anti-heart failure drugs and dexrazoxane are important for the prevention and treatment of CTRCD.Patients with advanced heart failure may also benefit from mechanical treatments including cardiac resynchronization therapy and mechanically-assisted ventricular devices.This article reviews the recent advances in the prevention and treatment of CTRCD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3881/j.issn.1000-503X.11380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carfilzomib-induced pulmonary hypertension in a patient with multiple myeloma.
J Cardiol Cases
November 2024
Division of Cardiology, Teine Keijinkai Hospital, Sapporo, Japan.
Article Synopsis
- A 59-year-old female with multiple myeloma developed symptoms of edema and dyspnea after starting treatment with carfilzomib, a cancer drug, which raised concerns about potential drug-related cardiac complications.
- Diagnostic tests revealed signs of pre-capillary pulmonary hypertension (PH) and confirmed it through right heart catheterization, leading to the conclusion that carfilzomib was causing the condition.
- After stopping the drug and starting pulmonary vasodilator therapy, the patient experienced symptom improvement and heart changes, suggesting the need for careful monitoring for PH in patients receiving carfilzomib.
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics-Related Cardiac Dysfunction.
JACC CardioOncol
October 2024
Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
Article Synopsis
- The study investigates the long-term outcomes for cancer patients with improved heart function who discontinue cardioprotective therapy (CPT) after experiencing cancer treatment-related cardiac dysfunction (CTRCD).
- Out of 134 patients analyzed, those who withdrew from CPT showed a significant decline in heart function (LVEF) compared to those who continued the therapy, especially in patients with initially low LVEF (<45%).
- Overall, withdrawing from CPT was associated with a higher rate of major clinical events, indicating that continuing therapy may be beneficial for patients with improved CTRCD.
Cancer-on-chip: a breakthrough organ-on-a-chip technology in cancer cell modeling.
Med Biol Eng Comput
February 2025
Institute of Physical Chemistry, Polish Academy of Sciences, Marcina Kasprzaka 44/52, 01-224, Warsaw, Poland.
Article Synopsis
- - Cancer is a top cause of death globally, and understanding its complex mechanisms is essential for developing effective treatments, making innovative approaches crucial.
- - Organ-on-a-chip (OoC) technology is emerging as a promising solution for the pharmaceutical industry, helping to reduce research costs and improve cancer treatment simulations in a 3D microenvironment.
- - This article reviews recent advancements in OoC systems, highlighting their potential for better tumor modeling, and examines both the benefits and drawbacks of using this technology in cancer therapy.
Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Circ Cardiovasc Qual Outcomes
January 2025
Section of Cardiovascular Medicine, Department of Internal Medicine (E.K.O., V.S., L.S.D., A.A., H.M.K., L.A.B., R.K.), Yale School of Medicine, New Haven, CT.
Article Synopsis
- Researchers evaluated the potential of artificial intelligence (AI) applied to electrocardiograms (ECG) to predict cardiac dysfunction related to cancer treatments, aiming to develop a more scalable risk stratification method.
- In a study involving 1,550 patients treated with anthracyclines and/or trastuzumab, the AI model classified patients into low, intermediate, and high-risk groups based on their baseline ECG images.
- The findings revealed that patients in the high-risk group had significantly higher incidents of cardiac dysfunction within a year post-treatment, highlighting the effectiveness of AI-ECG in identifying those at greater risk for complications.
Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images.
medRxiv
March 2024
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Article Synopsis
- This study explores an AI-enhanced electrocardiogram (AI-ECG) as a tool for risk stratification in patients at risk of cancer therapeutics-related cardiac dysfunction (CTRCD) rather than relying solely on specialized imaging techniques.
- Patients with breast cancer or non-Hodgkin lymphoma who received certain chemotherapy agents were analyzed, revealing that higher AI-ECG predictions of left ventricular systolic dysfunction (LVSD) correlated with worse heart function metrics and increased risk of future cardiac issues.
- The findings suggest that using AI on ECGs can effectively identify patients at greater risk for CTRCD associated with specific cancer treatments, potentially allowing for better management of these patients' heart health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!